What Should Specialty Pharmacists Know About the ReDOS Clinical Trial?

Article
Conference|Gastrointestinal Cancers Symposium

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.

Related Videos
Image Credit: Adobe Stock - nataliaderiabina
Credit: Adobe Stock - Tierney
ipopba - stock.adobe.com
lexiconimages - stock.adobe.com
https://www.youtube.com/watch?v=Q-WCvWaAcC8
Yaruniv-Studio - stock.adobe.com
Credit: Karanov images - stock.adobe.com
Technician- © pharmacytimes
Related Content

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

Osimertinib, Chemotherapy Show Survival Benefit for Patients With Advanced, Mutated Lung Cancer

September 11th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

Osimertinib, Chemotherapy Show Survival Benefit for Patients With Advanced, Mutated Lung Cancer

September 11th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

Osimertinib, Chemotherapy Show Survival Benefit for Patients With Advanced, Mutated Lung Cancer

September 11th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023
© 2023 MJH Life Sciences

All rights reserved.